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Decision Counseling in Prostate Cancer Screening 
___________________________________________________________________ 
 
In 2004, there will be an estimated 230,110 new cases of prostate cancer and 
29,900 deaths from this disease in the United States.1 Prostate cancer is often 
diagnosed through screening.  However, the practice of screening for prostate cancer 
is controversial. Proponents of prostate cancer screening believe that screening with 
the combination of routine digital rectal examination (DRE) and prostate specific 
antigen (PSA) testing is justified for men who have a reasonable life expectancy and 
is especially important for men at increased risk. It is argued that combined DRE and 
PSA testing is effective at identifying men with early prostate cancer.  Further, it is 
asserted that men who are diagnosed with and treated aggressively for localized 
prostate cancer have higher survival rates as compared to men diagnosed with late-
stage disease. The American Cancer Society and the American Urological Association 
recommend that health care providers offer annual DRE and PSA testing for men 
who are 50 or more years of age.1,2 These organizations also suggest that screening 
may be initiated at age 45 for African American men and those who have a family 
history of prostate cancer. 
 
Caution has been urged regarding prostate cancer screening, however, because no 
randomized trials have demonstrated that early detection reduces mortality from 
prostate cancer.  Definitive results concerning screening efficacy from randomized 
trials that are now underway are not yet available.  Concern about prostate cancer 
early detection is also based on the fact that treatment of early-stage prostate 
cancer can cause substantial adverse outcomes (e.g., impotence, incontinence, 
bowel injury, mortality). Guidelines put forward by the United States Preventive 
Services Taskforce (USPSTF), American College of Physicians, and the Canadian 
Taskforce on the Periodic Health Examination do not endorse routine prostate cancer 
screening.3-5 
While there is not consensus about whether prostate cancer screening should be 
performed routinely, there is widespread agreement that objective information about 
the potential benefits and harms of prostate cancer screening should be provided to 
older asymptomatic men. The USPSTF explicitly recommends that counseling be 
provided to men in order to facilitate informed decision making about screening, 
noting that “the proper choice for an individual (concerning prostate cancer 
screening) is highly dependent on personal preferences.”4 This recommendation is 
important because it recognizes that helping people make decisions about 
controversial issues like whether or not to have prostate cancer screening entails 
both the provision of information and the clarification of personal values. 
 
Research is needed to identify methods that enable men to systematically consider 
available information on screening and personal values related to screening, weigh 
positive and negative aspects of the main decision alternatives (to screen or not to 
screen), clarify personal preference, and make a decision about whether or not to 
have a screening exam. To address this need, investigators at Thomas Jefferson 
University and Einstein Health Care Network are conducting a three-year prospective 
randomized controlled trial entitled “Decision Counseling in Prostate Cancer 
Screening.” This investigation is a two-arm trial that will involve older adult men who 
are patients in two primary care practices. 
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The specific aims of the study are to: 
 
• develop effective methods for educating men about prostate cancer and 
screening 
 
• prepare men to make an informed, value-based decision about whether to 
have a prostate cancer screening exam 
 
• test the impact of providing information plus decision counseling related to 
prostate cancer screening as compared to providing information only 
 
The impact of the intervention will be measured in terms of the following primary 
outcomes: 
 
• knowledge about prostate cancer and screening 
 




• prostate cancer screening use 
 
Secondary outcomes to be measured include patient perceptions related to certain 
aspects of concern about decision making (i.e., feeling better informed, being clear 
about personal values, and believing that one has made a good decision), the 
completeness of decision making, and patient decision stage. 
 
Findings from this study will be disseminated to primary care practices affiliated with 
the Jefferson Health System (Albert Einstein Medical Center, Geisinger Health 
System, Wilmington Veteran’s Administration Hospital, Methodist Hospital, Thomas 
Jefferson University Hospital, and Christiana Hospital). Opportunities for integrating 
effective intervention components into the health care system will be identified. 
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